International Journal of Clinical Research
International Journal of Clinical Research. 2026; 10: (6) ; 10.12208/j.ijcr.20260276 .
总浏览量: 59
1 大理大学临床医学院 云南大理;
2 云南大学附属医院 云南昆明;
*通讯作者： 白丽萍,单位： 云南大学附属医院 云南昆明; ；李兴统,单位： 云南大学附属医院 云南昆明; ；
肝纤维化是各种慢性肝病发展为终末期肝病的必经病理阶段，是慢性肝病演变为肝硬化、肝癌和死亡等长期临床结果的关键决定因素。其病理过程复杂，受多细胞、多介质和多条信号通路调控。越来越多证据表明，血管新生在肝纤维化进展中起着关键作用；肝星状细胞是肝纤维化形成的核心，亦是炎症、纤维化和血管新生之间的交汇点。二者在肝纤维化的发生发展中相互促进，但现有文献较为零散。本文梳理近10年研究，系统阐述血管新生在肝纤维化中的作用机制，为肝纤维化的精准治疗提供新思路。
Hepatic fibrosis is a critical pathological stage in the progression of various chronic liver diseases to end-stage liver disease. It is a key determinant of the long-term clinical outcomes, including cirrhosis, liver cancer, and death. Its pathological process is complex and regulated by multiple cells, multiple mediators, and multiple signaling pathways. A growing body of evidence suggests that angiogenesis plays a key role in the progression of hepatic fibrosis; hepatic stellate cells are the core of hepatic fibrosis formation and also the intersection between inflammation, fibrosis, and angiogenesis. The two promote each other in the occurrence and development of hepatic fibrosis, but the existing literature is relatively scattered. This article reviews the research of the past decade, systematically elaborates on the mechanism of action of angiogenesis in hepatic fibrosis, and provides new ideas for the precise treatment of hepatic fibrosis.
[1] Shan L, Liu Z N, Ci L L, et al. Research progress on the anti-hepatic fibrosis action and mechanism of natural products[J]. International Immunopharmacol,2019,75: 105765.
[2] Roehlen N, Crouchet E, Baumert T F. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells,2020,9(4):875.
[3] Cigrovski BM, Virovic-Jukic L, Bilic-cucic I, et al. Post-transplant diabetes mellitus and preexisting liver disease-a bidirectional relationship affecting treatment and management [J]. World Journal of Gastroenterol,2020, 26(21):2740-2757.
[4] Liu S, Wan H, Yang L, et al. High prevalence of steatotic liver disease and fibrosis in the general population: A large prospective study in China[J].Journal of Hepatology, 2025,82(1):e23-e25.
[5] Shenoda B, Boselli J. Vascular syndromes in liver cirrhosis[J]. Clinical Journal of Gastroenterology,2019, 12(5):387-97.
[6] 钟培玲，陈英杰，柳臻，等.软肝颗粒抑制血管新生的抗肝纤维化作用机制研究[J].中西医结合肝病杂志，2021,31(1):30-33.
[7] Zadorozhna M, Di Gioia S, Conese M, et al. Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment. Molecular Biology Reports .2020 Mar;47(3):2279-2288.
[8] 高俪原,梁宝瑜,金春,等.血管新生在肝脏疾病发生与发展中作用的研究进展[J].生理科学进展,2020,51(03): 193-197.
[9] Li H. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis,cirrhosis and hepatocellular carcinoma[J]. Digestive and Liver Disease,2022,54(5):598-613.
[10] 孙 鑫，刘洪亮，黄 恺，等.虫草菌丝中3种活性成分对血管新生与内皮细胞功能的影响[J].中草药，2017,48（24）:5217-5223.
[11] 林媛,刘志敏,董梦琦,等.肝脏血管认知更新与研究新思路[J].南方医科大学学报,2022,42(12):1907-1911.
[12] Lin Y, Dong MQ, Liu ZM, et al. A strategy of vascular-targeted therapy for liver fibrosis. Hepatology. 2022 Sep;76(3):660-675.
[13] 王龙，冯贤荣，杨宇,等.开玄通络法调控肝窦内皮细胞窗孔抗肝纤维化的理论基础分析[J].中西医结合肝病杂志，2021,31(9):842-844.无内容对应
[14] WANG L, LIU X, ZHUANG H. Cellular mechanisms in liver fibrosis regression[J]. Journal Clinical Hepatol, 2018, 34 (4) :862-866.
[15] 于子越,蔺鑫,韩英,等.肝血窦内皮细胞在肝再生和肝纤维化发生中的作用[J].临床肝胆病杂志,2019,35(09): 2072-2074.
[16] Liu L, You Z, Yu H, et al. Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis. Nat Mater. 2017 Dec;16(12):1252-1261.
[17] KISSELEVA T,BRENNER D.Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol epatol,2021,18(3):151-166.
[18] Huang P,Ma H,Cao Y,et al. Activation of primary hepatic stellate cells and liver fibrosis induced by targeting TGF-β1/Smad signaling in schistosomiasis in mice [J].Parasit Vectors,2022,15(1):456.
[19] Wei W,Lin C,Hu R,et al.LOC102553417 silencing facilitates the apoptosis of hepatic stellate cells via the miR-30e/MTDH axis [J]. Mol Med Rep,2022,26(5):349.
[20] Yang LX, Qi C, Lu S. et al. Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells [J]. Nat Commun 16, 524 (2025).
[21] 邢安丽,赵鲲鹏,张秋菊,等.舒肝化癥方对肝纤维化模型大鼠VEGF、CTGF、CD31及vWF表达的影响及其相关性研究[J].中医药信息,2024,41(06):19-27.
[22] ROSMORDUC O,HOUSSET C. Hypoxia:A link between fibrogenesis,angiogenesis,and carcinogenesis in liver disease[J]. Semin Liver Dis,2010,30(3):258-270.
[23] 李志国,杨先照,李小科,等.缺氧微环境与肝病发生发展的关系[J].临床肝胆病杂志,2020,36(08):1891-1895.
[24] Wang P,Fang Y,Qiu J N,et al.miR-345-5p curbs hepatic stellate cell activation and liver fibrosis progression by suppressing hypoxia-inducible factor-1alpha expression[J]. Toxicol Lett,2022,370:42-52.
[25] Kou K,Li S X,Qiu W,et al.Hypoxia-inducible factor 1α/IL-6 axis in activated hepatic stellate cells aggravates liver fibrosis[J].Biochem Biophys Res Commun,2023,653: 21-30.
[26] Lin Y, Dong MQ, Liu ZM, Xu M, Huang ZH, Liu HJ, Gao Y, Zhou WJ. A strategy of vascular-targeted therapy for liver fibrosis. Hepatology. 2022 Sep;76(3):660-675.
[27] Li H.Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma[J].Expert Rev Gastroenterol Hepatol,2021,15(3):217-233.
[28] Mesarwi O A,Moya E A,Zhen X,et al.Hepatocyte HIF-1 and intermittent hypoxia independently impact liver fibrosis in murine nonalcoholic fatty liver disease[J].Am J Respir Cell Mol Biol,2021,65(4):390-402.
[29] Liu Y,Lu T F,Zhang C,et al.Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury[J].J Hepatol,2019,71(4):719-730.
[30] Testoni B,Levrero M,Zoulim F. Chal enges to a cure for HBV infection[J]. Semin Liver Dis,2017,37(3):231-242.
[31] Rosmorduc O, Housset C. Hypoxia: A link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease[J]. Semin Liver Dis,2010,30(3):258-270.
[32] Zhan L,Huang C,Meng X M,et al.Hypoxia-inducible factor-1alpha in hepatic fibrosis:a promising therapeutic target[J].Biochimie,2015,108:1-7.
[33] 金星，尹明实.糜酶抑制剂对肝纤维化大鼠肝组织α-平滑肌肌动蛋白和Ⅰ型胶原蛋白表达的抑制作用[J].延边大学医学学报，2020,43(3):162-164.
[34] 周丹,张立婷,李俊峰,等.缺氧诱导因子1α在肝纤维化发生发展中的作用机制[J].临床肝胆病杂志,2019, 35(7): 1604-1607.
[35] 姜娜, 平键, 徐列明.肝星状细胞的活化机制—探寻肝纤维化新的诊断指标和治疗靶点[J].Journal of Clinical Hepatology, 2019,35(3):640.
[36] 吕超，毛德文，石清兰，等.中药及其复方抗肝纤维化作用机制的研究进展[J].中国实验方剂学杂志，2020,26(4): 242-250.
[37] Kwon SH,Jeong SW,JANG J Y,et al. Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis,cirrhosis and hepatocellular carcinoma[J]. Clin Mol Hepatol,2012,18(3):287.
[38] 金鑫,毛熙贤,艾麦提·牙森,等.TGF-β1激活肝星状细胞并促进血管内皮细胞新生血管形成[J].中国细胞生物学学报,2018,40(04):515-521.
[39] 邢安丽,赵鲲鹏,张秋菊,等.舒肝化癥方对肝纤维化模型大鼠VEGF、CTGF、CD31及vWF表达的影响及其相关性研究[J].中医药信息,2024,41(06):19-27.
[40] 吴聪，张荣臻，王挺帅，等.细胞因子对肝纤维化发展影响的研究进展[J].海南医学院学报，2021,27(13):1036-1040.
[41] Zhou J,Liang Y,Pan J X,et al.Protein extracts of Crassostrea gigas alleviate CCl-induced hepatic fibrosis in rats by reducing the expression of CTGF,TGF-β1and NF-κB in liver tissues[J].Mol Med Rep,2015,11(4):2913-2920.
[42] 鲁军，周凝，黄棪，等.疏肝健脾活血方对肝星状细胞/肝窦内皮细胞共培养体系中VEGF/VEGFR表达的影响[J].中医杂志，2019,60(3):242-247.
[43] 张荣，刘绍能，周海艳，等.芪术颗粒对肝纤维化模型大鼠肝窦微血管新生的影响及其机制研究[J].中药新药与临床药理，2019,30(6):659-663.
[44] Navarro-corcueraa,Ansorena E,Montiel-du-arte C,et al.AGAP2:modulating TGFbeta1-signaling in the regulation of liver fibrosis[J].Int J Mol Sci,2020,21(4):1400.
[45] Lee J S,Semela D,Iredale J,et al.Sinusoidal remodeling and angiogenesis:a new function for the liver-specific pericyte[J].Hepatology,2007,45(3):817-825.
[46] Moreno-Alvarez P,Sosa-Garrocho M,Briones-or-TA M A,et al.AngiotensinⅡincreases m RNA levels of all TGF-beta isoforms in quiescent and activated rat hepatic stellate cells[J].Cell Biol Int,2010,34(10):969-978.
[47] Chen Y,Fan Y,Guo D,et al.Study on the relationship between hepatic fibrosis and epithelial-mesenchymal transition in intrahepatic cells[J].Biomed Pharmacother, 2020,129:110413.